| Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long‐term engraftment and no ectopic tissue formation L Von Bahr, I Batsis, G Moll, M Hägg, A Szakos, B Sundberg, M Uzunel, ... Stem cells 30 (7), 1575-1578, 2012 | 631 | 2012 |
| Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? G Moll, JJ Alm, LC Davies, L von Bahr, N Heldring, L Stenbeck-Funke, ... Stem cells 32 (9), 2430-2442, 2014 | 393 | 2014 |
| Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines G Moll, JA Ankrum, J Kamhieh-Milz, K Bieback, O Ringdén, HD Volk, ... Trends in molecular medicine 25 (2), 149-163, 2019 | 375 | 2019 |
| Are therapeutic human mesenchymal stromal cells compatible with human blood? G Moll, I Rasmusson-Duprez, L von Bahr, AM Connolly-Andersen, ... Stem cells 30 (7), 1565-1574, 2012 | 374 | 2012 |
| Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements J Doorn, G Moll, K Le Blanc, C Van Blitterswijk, J de Boer Tissue Engineering Part B: Reviews 18 (2), 101-115, 2012 | 366 | 2012 |
| Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application H Caplan, SD Olson, A Kumar, M George, KS Prabhakara, P Wenzel, ... Frontiers in immunology 10, 1645, 2019 | 270 | 2019 |
| Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses G Moll, R Jitschin, L von Bahr, I Rasmusson-Duprez, B Sundberg, ... PloS one 6 (7), e21703, 2011 | 180 | 2011 |
| Galectin-1 mediated suppression of Epstein-Barr virus–specific T-cell immunity in classic Hodgkin lymphoma MK Gandhi, G Moll, C Smith, U Dua, E Lambley, O Ramuz, D Gill, ... Blood, The Journal of the American Society of Hematology 110 (4), 1326-1329, 2007 | 180 | 2007 |
| MSC therapies for COVID-19: importance of patient coagulopathy, thromboprophylaxis, cell product quality and mode of delivery for treatment safety and efficacy G Moll, N Drzeniek, J Kamhieh-Milz, S Geissler, HD Volk, P Reinke Frontiers in immunology 11, 1091, 2020 | 174 | 2020 |
| Cryopreserved or Fresh Mesenchymal Stromal Cells: Only a Matter of Taste or Key to Unleash the Full Clinical Potential of MSC Therapy? G Moll, S Geißler, R Catar, L Ignatowicz, MJ Hoogduijn, D Strunk, ... Biobanking and Cryopreservation of Stem Cells 951, 77-98, 2016 | 168 | 2016 |
| Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial A Roemhild, NM Otto, G Moll, M Abou-El-Enein, D Kaiser, G Bold, ... bmj 371, 2020 | 156 | 2020 |
| Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua G Moll, L Ignatowicz, R Catar, C Luecht, B Sadeghi, O Hamad, ... Stem cells and development 24 (19), 2269-2279, 2015 | 128 | 2015 |
| Crimean-Congo hemorrhagic fever virus activates endothelial cells AM Connolly-Andersen, G Moll, C Andersson, S Åkerström, H Karlberg, ... Journal of virology 85 (15), 7766-7774, 2011 | 118 | 2011 |
| Improved MSC minimal criteria to maximize patient safety: a call to embrace tissue factor and hemocompatibility assessment of MSC products G Moll, JA Ankrum, SD Olson, JA Nolta Stem cells translational medicine 11 (1), 2-13, 2022 | 117 | 2022 |
| Impact of cryopreservation and freeze-thawing on therapeutic properties of mesenchymal stromal/stem cells and other common cellular therapeutics C Cottle, AP Porter, A Lipat, C Turner-Lyles, J Nguyen, G Moll, ... Current stem cell reports 8 (2), 72-92, 2022 | 101 | 2022 |
| Placenta-derived decidua stromal cells for treatment of severe acute graft-versus-host disease O Ringden, A Baygan, M Remberger, B Gustafsson, J Winiarski, B Khoein, ... Stem Cells Translational Medicine 7 (4), 325-331, 2018 | 99 | 2018 |
| Alterations in the cellular immune compartment of patients treated with third‐party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation R Jitschin, D Mougiakakos, L Von Bahr, S Völkl, G Moll, O Ringden, ... Stem Cells 31 (8), 1715-1725, 2013 | 97 | 2013 |
| Editorial: Safety, Efficacy and Mechanism of Action of Mesenchymal Stem Cell Therapies G Moll, MJ Hoogduijn, JA Ankrum Frontiers in Immunology 11, 243, 2020 | 94 | 2020 |
| Multi-Parameter Analysis of Biobanked Human Bone Marrow Stromal Cells Shows Little Influence for Donor Age and Mild Comorbidities on Phenotypic and Functional Properties. A Andrzejewska, R Catar, J Schoon, TH Qazi, FA Sass, D Jacobi, ... Frontiers in Immunology 10 (2474), 1-24, 2019 | 86 | 2019 |
| Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells? G Moll, A Hult, L Bahr, JJ Alm, N Heldring, OA Hamad, L Stenbeck-Funke, ... PLoS one 9 (1), e85040, 2014 | 85 | 2014 |
Rusan CatarPhDEmail verificata su charite.de